Giacomo Iovane^1,*, Luca Traman², Michele Maffezzoli^1,3, Giuseppe Fornarini², Domenico Corradi⁴, Debora Guareschi⁴, Matteo Santoni^5,#, Sebastiano Buti^1,#

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070523 - 30 December 2025

Abstract Background: While the treatment of metastatic renal cell carcinoma (mRCC) is evolving due to immune checkpoint inhibitors (ICIs), optimal strategies for later lines of therapy have yet to be defined. The combination of lenvatinib and everolimus represents a viable option, and the present review aimed to summarize its activity, effectiveness, and safety. Methods: A systematic review of the literature was conducted using PubMed, targeting studies published between 2018 and 2025. Eligible studies included English-language prospective and retrospective trials reporting survival outcomes in mRCC patients treated with lenvatinib and everolimus after at least one ICI-containing regimen. Results:… More > Graphic Abstract

Jiayin Peng^1,2,#, Yijun Xue^2,#, Zhiren Cai², Zhaoguan Li², Kangyan Han², Xiaoqi Lin², Yutong Li^1,*, Yumin Zhuo^1,*

Oncology Research, Vol.33, No.10, pp. 3127-3154, 2025, DOI:10.32604/or.2025.067340 - 26 September 2025

Abstract Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy associated with limited treatment options and poor prognosis. Emerging studies suggest that the actin-regulating protein actin-related protein 2/3 complex subunit 1B (ARPC1B), a key regulatory protein within the actin cytoskeleton, could play a pivotal role in ccRCC progression. The current study aimed to uncover the biological functions of ARPC1B and the molecular mechanisms driving its effects in ccRCC. Methods: ARPC1B expression and prognostic implications were analyzed using data sourced from the Gene Expression Profiling Interactive Analysis (GEPIA) platform, immunohistochemical (IHC) staining on 150 tumor… More >

NAIXIONG PENG, YUEFENG CAI, DONG CHEN, LING DENG, ZEJIAN ZHANG, WEI LI^*

Oncology Research, Vol.33, No.2, pp. 347-356, 2025, DOI:10.32604/or.2024.056039 - 16 January 2025

Abstract Background: Clear cell renal carcinoma (ccRCC), the leading histological subtype of RCC, lacks any targeted therapy options. Although some studies have shown that early growth response factor 1 (EGR1) has a significant role in cancer development and progression, its role and underlying mechanisms in ccRCC remain poorly understood. Methods: The Cancer Genome Atlas (TCGA) database was utilized to examine the expression of EGR1 in ccRCC. The expression of EGR1 in 55 ccRCC tissues was evaluated using immunohistochemistry. The link between EGR1 expression and clinicopathological variables was examined through an analysis. Gain-of-function assays were employed to… More >

ENRICO CALIMAN^1,2, SARA FANCELLI^1,2, FEDERICO SCOLARI³, ADRIANO PASQUI⁴, CLARA MANNESCHI⁴, DANIELE LAVACCHI¹, FRANCESCA MAZZONI⁴, FRANCESCA GENSINI⁵, VALERIA PASINI⁶, CAMILLA EVA COMIN^2,7, LUCA VOLTOLINI^2,8, SERENA PILLOZZI^1,2,*, LORENZO ANTONUZZO^1,2,4

Oncology Research, Vol.33, No.1, pp. 45-55, 2025, DOI:10.32604/or.2024.050161 - 20 December 2024

Abstract Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients’ survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes—namely ERCC1, ERCC2,… More >

WEIGANG REN^1,#, JING LI^2,#, RUIJIANG ZENG^3,4, LIANG ZHU^3,4,*

BIOCELL, Vol.48, No.9, pp. 1323-1330, 2024, DOI:10.32604/biocell.2024.051747 - 04 September 2024

Abstract Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys. ccRCC is well known as a type of tumour with immunogenicity. Immune checkpoint inhibitors (ICIs) aim to enhance the anticancer immune response in ccRCC by blocking programmed cell death 1 ligand 1/programmed death 1 (PD-L1/PD-1) pathways. In a previous study, we showed that RING finger protein 26 (RNF26) degrades chromobox 7 (CBX7) to activate the tumor necrosis factor (TNF) in ccRCC. Methods: We analyzed The Cancer Genome Atlas (TCGA)… More > Graphic Abstract

KAIWEN TIAN^#, HANZHONG CHEN^#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG^*, JIUMIN LIU^*

BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737 - 06 May 2024

Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

WENFEI GE^1,#, SHIYAN SONG^1,#, XIAOCHEN QI^1,#, FENG CHEN^1,#, XIANGYU CHE¹, YONGHAO SUN¹, JIN WANG¹, XIAOWEI LI², NANA LIU³, QIFEI WANG^1,*, GUANGZHEN WU^1,*

Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942 - 22 May 2023

Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More > Graphic Abstract

Aparna Gullapelly, Barnali Gupta Banik^*

Computer Systems Science and Engineering, Vol.46, No.1, pp. 1127-1139, 2023, DOI:10.32604/csse.2023.032904 - 20 January 2023

Abstract The field of object tracking has recently made significant progress. Particularly, the performance results in both deep learning and correlation filters, based trackers achieved effective tracking performance. Moreover, there are still some difficulties with object tracking for example illumination and deformation (DEF). The precision and accuracy of tracking algorithms suffer from the effects of such occurrences. For this situation, finding a solution is important. This research proposes a new tracking algorithm to handle this problem. The features are extracted by using Modified LeNet-5, and the precision and accuracy are improved by developing the Real-Time Cross-modality… More >

Dayu Tian¹, Yang Shi¹, Li Lei¹, Xiangmin Qiu¹, Tao Song^2,*, Qianyin Li^1,*

Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838 - 29 June 2022

Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related… More >

Jian Li^1,3, Weijian Zhang¹, Yating Hu^1,4, Xiaoguang Li^2,*, Zhun Wang¹

CMC-Computers, Materials & Continua, Vol.69, No.2, pp. 2493-2511, 2021, DOI:10.32604/cmc.2021.018743 - 21 July 2021

Abstract This paper proposes a formation of multiple unmanned aerial vehicles (UAVs) based on the R5DOS (RCC-5 and orientation direction) intersection model. After improving the R5DOS-intersection model, we evenly arranged 16 UAVs in 16 spatial regions. Compared with those of the rectangular formation model and the grid formation model, the communication costs, time costs, and energy costs of the R5DOS model formation were effectively reduced. At the same time, the operation time of UAV formation was significantly enhanced. The leader-follower method can enhance the robustness of the UAV formation and ensure the integrity of communication during… More >